Discrepant Results of Experimental Human Mesenchymal Stromal Cell Therapy after Myocardial Infarction: Are Animal Models Robust Enough?

Abstract

BackgroundHuman mesenchymal stromal cells (MSCs) have been reported to preserve cardiac function in myocardial infarction (MI) models. Previously, we found a beneficial effect of intramyocardial injection of unstimulated human MSCs (uMSCs) on cardiac function after permanent coronary artery ligation. In the present study we aimed to extend this research by investigating the effect of intramyocardial injection of human MSCs pre-stimulated with the pro-inflammatory cytokine interferon-gamma (iMSCs), since pro-inflammatory priming has shown additional salutary effects in multiple experimental disease models.MethodsMI was induced in NOD/Scid mice by permanent ligation of the left anterior descending coronary artery. Animals received intramyocardial injection of uMSCs, iMSCs or PBS. Sham-operated animals were used to determine baseline characteristics. Cardiac performance was assessed after 2 and 14 days using 7-Tesla magnetic resonance imaging and pressure-volume loop measurements. Histology and q-PCR were used to confirm MSC engraftment in the heart.ResultsBoth uMSC and iMSC therapy had no significant beneficial effect on cardiac function or remodelling in contrast to our previous studies.ConclusionsAnimal models for cardiac MSC therapy appear less robust than initially envisioned.

Chitosan hydrogel improves mesenchymal stem cell transplant survival and cardiac function following myocardial infarction in rats

“…Therefore, MSCs have been widely used in experimental animal ( 8 ) and clinical studies ( 9 ), for cardiac repair and regeneration following MI. However, the effectiveness of MSCs in the heart has not yet been fully elucidated; MSC therapy in post-MI animal models has demonstrated only modest or transient functional improvements ( 10 , 11 ). This is may be due to lower retention rates, low survival rates of transplanted MSCs and inefficient cardiomyocyte differentiation of MSCs in vivo ( 12 , 13 ).…”

Silica Nanoparticles Actively Engage With Mesenchymal Stem Cells in Improving Acute Functional Cardiac Integration

“…This might improve the success of the MSC-based therapeutic approach. Although a number of studies aim to improve MSC survival at the site of transplantation, yet few effective solutions have been proposed to solve the problem of weak cell-ECM adhesion [7,8].…”

Deepening a Simple Question: Can MSCs Be Used to Treat Cancer?

“…Pre-clinical studies support functional recovery after MSCs transplantation in diverse pathologies (10)(11)(12)(13)(14)(15). Many of these studies show significant therapeutic benefits of cell transplantation even when exogenous cells are not present in the target tissues.…”